Our results confirm previous findings of a low mutation rate of p53 in MM and suggest that understanding the details of G1/S and G2/M control checkpoints in mesothelioma cell lines may prove critical to the development of potential novel therapeutic strategies, especially based on the triggering of apoptosis. This evidence concerns the gene TP53 and Miyoshi myopathy.